Please login to the form below

Not currently logged in
Email:
Password:

BeiGene

This page shows the latest BeiGene news and features for those working in and with pharma, biotech and healthcare.

Celgene joins PD-1 race via partnership with BeiGene

Celgene joins PD-1 race via partnership with BeiGene

Celgene joins PD-1 race via partnership with BeiGene. The pharma giant will pay the Chinese firm up to $980m in milestone payments. ... Celgene's push into immuno-oncology has continued with a $1.4bn agreement to license ex-Asian rights to BeiGene's PD-1

Latest news

  • Merck KGaA to research cancer drug with Chinese biotech Merck KGaA to research cancer drug with Chinese biotech

    Merck KGaA has entered a collaboration with China-based biotech BeiGene to research a new treatment for cancer. ... The agreement sees Merck pay BeiGene an undisclosed upfront fee as well as several clinical and commercial milestones.

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    In particular, the third largest deal of the month is a joint venture between the research-based biotechnology company, BeiGene, which focuses on immuno-oncology, and the Guangzhou Development District. ... The agreement, worth $330m, will build BeiGene

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    BeiGene / Merck. Serono. Co-development. Expansion of collaboration to include BeiGene 290 for cancer.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics